Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
...Treatment and Manageme...
Who to T...
...ine Society (ES) recommends treating postmenopaus...
...Bisphosphonate...
...1: In postmenopausal women at high risk of...
...tmenopausal women with osteoporosis who are t...
...Den...
...enopausal women with osteoporosis who are at high...
...nopausal women with osteoporosis who are ta...
...3: In postmenopausal women with osteoporosis takin...
...Teriparatid...
...menopausal women with osteoporosis at very h...
...nopausal women with osteoporosis wh...
...Romosozu...
...n postmenopausal women with osteoporosis at very...
...postmenopausal women with osteoporosis who...
...nopausal women with osteoporosis at high...
...Menopausal Hor...
...n postmenopausal women at high risk...
...2: In postmenopausal women with osteopor...
...Cal...
...In postmenopausal women at high risk of...
...Calcium and Vit...
...1: In postmenopausal women with low BMD an...
...In postmenopausal women at high risk...
...Monitoring...
...: In postmenopausal women with a low...
...gorithm for the Management of Postmenopausal...